Lynx Delays Vote on Solexa Merger Until March; Expects Compliance with Nasdaq Regs | GenomeWeb

Lynx Therapeutics moved its delayed annual shareholders' meeting back, setting the new date for March 1, the company announced this week.

The Hayward, Calif.-based gene-expression services firm had initially chosen Feb. 17 for the first meeting of its shareholders since 2003. It is hoping to amass enough votes at the shareholder meeting to secure its merger with Solexa, an Essex, UK-based DNA-sequencing products developer, with whom it signed a definitive merger pact in September (see BAN 10/6/04).

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.